A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of VV116 After Multiple Ascending Doses Administered Orally to Chinese Healthy Volunteers
Latest Information Update: 14 Feb 2022
At a glance
- Drugs Deuremidevir hydrobromide (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 08 Feb 2022 Status changed from recruiting to completed.
- 27 Jan 2022 New trial record